Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RGNX |
---|---|---|
09:32 ET | 12744 | 16.34 |
09:34 ET | 6567 | 16.57 |
09:36 ET | 1137 | 16.575 |
09:38 ET | 1856 | 16.7129 |
09:39 ET | 3557 | 16.65 |
09:41 ET | 1000 | 16.58 |
09:43 ET | 795 | 16.52 |
09:45 ET | 1017 | 16.53 |
09:48 ET | 700 | 16.48 |
09:50 ET | 1743 | 16.49 |
09:52 ET | 824 | 16.465 |
09:54 ET | 3827 | 16.4 |
09:56 ET | 1517 | 16.355 |
09:57 ET | 900 | 16.3 |
09:59 ET | 300 | 16.26 |
10:01 ET | 100 | 16.245 |
10:03 ET | 500 | 16.235 |
10:06 ET | 100 | 16.2 |
10:08 ET | 200 | 16.1 |
10:10 ET | 993 | 16.165 |
10:12 ET | 625 | 16.24 |
10:14 ET | 100 | 16.235 |
10:15 ET | 573 | 16.2 |
10:17 ET | 330 | 16.25 |
10:21 ET | 100 | 16.25 |
10:24 ET | 200 | 16.265 |
10:30 ET | 200 | 16.19 |
10:32 ET | 617 | 16.203 |
10:37 ET | 100 | 16.18 |
10:39 ET | 5337 | 16.08 |
10:42 ET | 1008 | 16.1 |
10:44 ET | 200 | 16.1 |
10:46 ET | 5854 | 16.16 |
10:48 ET | 700 | 16.155 |
10:50 ET | 500 | 16.18 |
10:51 ET | 521 | 16.23 |
10:53 ET | 537 | 16.2 |
10:57 ET | 200 | 16.23 |
11:00 ET | 326 | 16.25 |
11:02 ET | 300 | 16.255 |
11:04 ET | 800 | 16.27 |
11:06 ET | 400 | 16.23 |
11:08 ET | 100 | 16.21 |
11:11 ET | 100 | 16.21 |
11:18 ET | 100 | 16.21 |
11:20 ET | 444 | 16.225 |
11:22 ET | 1400 | 16.25 |
11:24 ET | 8603 | 16.41 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Regenxbio Inc | 774.9M | -2.8x | --- |
SAGE Therapeutics Inc | 721.6M | -1.4x | --- |
Nurix Therapeutics Inc | 886.6M | -6.2x | --- |
CureVac NV | 695.3M | -2.5x | --- |
WAVE Life Sciences Ltd | 714.3M | -11.6x | --- |
Zymeworks Inc | 636.3M | -5.1x | --- |
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $774.9M |
---|---|
Revenue (TTM) | $86.7M |
Shares Outstanding | 49.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.36 |
EPS | $-5.88 |
Book Value | $7.08 |
P/E Ratio | -2.8x |
Price/Sales (TTM) | 8.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -306.52% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.